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ABSTRACT: It is quickly becoming apparent that situating
human variation in a pathway context is crucial to
understanding its phenotypic significance. Toward this
end, we have developed a general method for finding
pathways associated with traits that control for pathway
size. We have applied this method to a new whole genome
survey of coding SNP variation in 187 patients afflicted
with Parkinson disease (PD) and 187 controls. We show
that our dataset provides an independent replication of the
axon guidance association recently reported by Lesnick
et al. [PLoS Genet 2007;3:e98], and also indicates that
variation in the ubiquitin-mediated proteolysis and T-cell
receptor signaling pathways may predict PD susceptibility.
Given this result, it is reasonable to hypothesize that
pathway associations are more replicable than individual
SNP associations in whole genome association studies.
However, this hypothesis is complicated by a detailed
comparison of our dataset to the second recent PD
association study by Fung et al. [Lancet Neurol
2006;5:911–916]. Surprisingly, we find that the axon
guidance pathway does not rank at the very top of the
Fung dataset after controlling for pathway size. More
generally, in comparing the studies, we find that SNP
frequencies replicate well despite technologically different
assays, but that both SNP and pathway associations are
globally uncorrelated across studies. We thus have a
situation in which an association between axon guidance
pathway variation and PD has been found in 2 out of 3
studies. We conclude by relating this seeming inconsis-
tency to the molecular heterogeneity of PD, and suggest
future analyses that may resolve such discrepancies.
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Introduction
Many of the recent genome-wide association (GWA) studies of
complex traits have failed to find individual SNPs of reproducibly
large effect. An increasingly popular hypothesis for this phenom-
enon is that variation at the pathway level is more consistently
correlated with variation in a trait than variation in individual
SNPs. To investigate this hypothesis, we developed a novel method
for ranking pathways by their degree of association with a complex
trait. We applied this method to a new whole genome association
study of Parkinson disease (PD) to provide an independent
replication of the previously reported association between axon
guidance and PD. However, we also show that this pathway
association is statistically significant in only 2 out of 3 studies,
complicating the hypothesis of pathway reproducibility. Idiopathic
PD is likely to result from a combination of environmental and
genetic factors. With regard to the latter, a great deal of research
has focused on finding functionally significant polymorphisms
that increase the probability of developing PD, with both
candidate gene [Grevle et al., 2000; Le and Appel, 2004; Marx
et al., 2003; Mellick et al., 1999; Nicholl et al., 1999; Xu et al., 2002;
Zheng et al., 2003] and GWA studies [Maraganore et al., 2005]
conducted in recent years. While the candidate genes were
identified on the basis of involvement in a biological pathway
plausibly linked to the degenerative process that underlies PD, the
GWA studies were designed to be unbiased scans for associated
SNPs across the genome.
However, problems have arisen with both of these approaches.
While several candidate genes like LRRK2 (MIM] 609007), SNCA
(MIM] 163890), DJ1 (HUGO-approved symbol PARK7; MIM]
602533), PINK1 (MIM] 608309), and Parkin (HUGO-approved
symbol PARK2; MIM] 602544) have been implicated in one or
more varieties of familial Parkinsonism [Klein and Schlossmacher,
2007], no single genetic susceptibility factor has yet been shown to
consistently increase the risk for PD. Similar inconsistencies have
been observed with the recent GWA studies of PD, in that separate
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reported in either the Fung et al. [2006] or the Maraganore
et al. [2005] studies ([Elbaz et al., 2006; Perez-Tur 2006] and
[Clarimon et al., 2006; Goris et al., 2006; Li et al., 2006; Myers,
2006], respectively). It is useful to put the problems of the
candidate gene and GWA approaches in perspective by regarding
them as two extremes on a continuum. The candidate gene
approach specifies ‘‘hard priors’’ that constrain the search space to
a small subset of all possible genetic predictors. Conversely, the
GWA approach discards all prior information, opening itself up to
the problem of massively multiple testing. It is likely that a better
solution lies in an intermediate between these two extremes, in
which gene function is used to flexibly constrain the set of possible
genotype-to-phenotype maps. An important step in this direction
was recently taken by Lesnick et al. [2007], who performed a
‘‘candidate pathway’’ analysis to demonstrate that variation in the
axon guidance pathway (KEGG:04360; see Kyoto Encyclopedia of
Genes and Genomes; www.genome.jp/kegg) could predict PD-
related traits. Specifically, they found that fitting different kinds of
regression models to a matrix of SNP dosage variation in the axon
guidance pathway allowed prediction of PD susceptibility, survival
times, and age-of-onset. However, because they did not have a
systematic means of comparing the association strengths of
different pathways, Lesnick et al. [2007] could not show that axon
guidance variation was significantly more associated with PD than
variation in other pathways.
Here, we address this issue by providing an algorithm for
ranking individual pathways by their degree of association with
PD susceptibility. We show that it is possible to control this
ranking for the critical confound of pathway size, thereby
preventing pathways from being deemed ‘‘strongly associated’’
simply because many of their SNPs were assayed on a chip. We
apply our techniques to both existing WGA studies [Fung et al.,
2006; Maraganore et al., 2005] of PD, as well as a new genome
wide screen for coding SNPs associated with idiopathic PD, in
which we used the Affymetrix MegAllele Genotyping Human 20K
cSNP chips (Affymetrix, Santa Clara, CA) to interrogate
approximately 20,000 SNPs (70% of which were coding) in 187
cases and 187 controls. This chip is particularly suitable for a
pathway-based analysis as it contains more coding (and hence
genic) SNPs than mapping chips in which most features are in
nongenic regions [Jorgenson and Witte, 2006], such as the
Affymetrix 500K (Affymetrix). Finally, we present a detailed
comparative analysis of all three datasets to determine which SNPs
and pathways show reproducible associations.
Materials and Methods
Our GWA study was performed with 374 Caucasians between
50 and 70 years of age, consisting of 187 controls and 187 cases
with PD. Institutional Review Board (IRB) approval was obtained
and a consent form was signed by all patients participating in this
study. Patients were diagnosed with PD if they satisfied the
following seven criteria: 1) at least 3 out of the 4 following cardinal
features of PD on neurological examination (resting tremor,
rigidity, bradykinesia, and postural instability); 2) a clear response
to levodopa; 3) an absence of clinical features suggesting atypical
parkinsonism; 4) age of onset over 50 years; 5) a disease duration
of 10 years or less (to avoid survivor bias); 6) non-Hispanic white;
and 7) no familial history of PD. Control subjects were non-
Hispanic whites without a history of known neurodegenerative
disorder. Each control was matched to a case of the same age and
gender.
Genotyping
Genomic DNA was extracted from blood and quantified by
spectrophotometer (Qiagen, Hilden, Germany). Extracted DNA
has a 260/280 spectroscopic absorbance ratio between 1.7 and 2,
and the DNA quality was also evaluated using gel electrophoresis.
Genotyping was performed with the Affymetrix MegAllele
Genotyping Human 20K cSNP chip (Affymetrix), and genotype
calls were performed with the Targeted Genotyping Analysis
(GTGS) package (Affymetrix). The 20K cSNP chip uses the
previously described molecular inversion probe technology
[Absalan and Ronaghi, 2007; Hardenbol et al., 2003] to
interrogate approximately 20,000 nonsynonymous cSNPs across
the human genome. By selecting a focused content panel of coding
SNPs, we concentrated our attention on the class of SNPs that
were most a priori likely to be biologically important [Jorgenson
and Witte, 2006].
To genotype the cSNPs, an Affymetrix MegAllele Genotyping
Human 20K cSNP was used (Affymetrix), which utilizes a single
molecular probe per SNP locus, designed to incorporate two
regions of DNA that are complementary to the genomic DNA on
either side of the SNP locus. The probes can be used in a single
panel for hybridization to genomic DNA. When the molecular
inversion probe has hybridized to the target SNP, it forms a
circular DNA molecule with a single-base gap. The SNP is located
at this single-base gap. The reaction is split into four aliquots and
a different dNTP is added to each aliquot. The single-base gap is
filled by a polymerization/ligation reaction. Different dNTPs are,
therefore, used to provide allele differentiation between the
aliquots. Exonuclease digestion of the extraneous linear DNA
results in the selection of only circularized DNA to participate
further in the assay. These probes are then, in turn, linearized and
released from the genomic DNA. The linearized probe has
undergone an inversion reaction and it can now serve as template
for subsequent amplification reactions. Each probe also contains a
unique tag sequence that is complementary to a sequence on a
GeneChip microarray. Following PCR, the amplified products are
hybridized to the Affymetrix GeneChip Universal Tag Array under
a single set of conditions. The unique advantage conferred by this
technology is the ability of the covalently closed circular probe to
suppress the cross-reactivity of competing hybridizations. This is
achieved during the exonuclease enzymatic step that digests all
linear DNA, leaving only circularized probes unaffected. It is at
this stage that all other incomplete probe sequences and genomic
DNA are eliminated from taking any further part in the assay
without affecting the signal from the circular DNA and ultimately
SNP sequence detection. The microarrays were scanned by the
Affymetrix GeneChip Scanner.
Data from the Affymetrix chips were stored in the Laboratory
Information Management Systems (LIMS) system. The tracking
database linked each sample ID, each probe pool ID, each plate
barcode tracking information, and each chip ID used for detection
of every sample and probe pool. Tag information from the probe
pool ID was used to extract signal feature data from the .cel files
for each of the A,C,G,T channels for every marker genotyped on
each sample. The tracking database stored information relating to
the quality control (QC) metric of the chip hybridization and
washing process, including border feature variation, chip to chip
variation, and variation among standard controls distributed
within each chip. This information was linked to the genotype call
as a flag to pull up any processing-related issues. In addition,
metrics relating to each chip, such as background level, noise on the
background level, and normalization information was recorded and
HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009 229linked to the raw genotype signal data. A cluster base-caller has
been used which uses the four signal measurements for each
genotype and the allele information for the marker to perform
cluster analysis based on an expectation-maximization (E-M)
algorithm. The resulting calls have confidence scores that can be
mapped to the accuracy of the call using reference sequencing on a
small number of markers in a few samples. In addition, the ability
to monitor all four bases for each genotype produced a signal-to-
noise (S/N) metric as well for every call, which is a further measure
of the integrity of the call. This S/N metric comprised a built-in
quality control for the entire genotyping process for every single call
made. Finally, the cluster analysis algorithm incorporated informa-
tion relating to the chip-processing quality metrics to flag any
quality control problems in that process.
Genotyping Validation With Pyrosequencing
Pyrosequencing primers for SNP analyses were designed by
SOP3, a free web-based software (http://imgen.ccbb.pitt.edu/sop3/).
Single-strand DNA preparation and sequencing primer hybridiza-
tion were performed semiautomatically using a Vacuum Prep Tool
and Vacuum Prep Worktable (Biotage AB, Uppsala, Sweden) as
described before [Gharizadeh et al., 2006]. Pyrosequencing
[Ronaghi et al., 1998] was performed on an automated plate-based
benchtop pyrosequencing (PSQ) system (Uppsala, Sweden) at a
dispensing pressure of 625 mbar with 4-msec open time and 65-sec
cycle time. The nucleotide dispensation order was set for each SNP.
The sequencing primers and the pyrosequencing SNP dispensation
orders can be found online (Table A: Amplification and Sequencing
Primers; www-sequence.stanford.edu:16080/pyrosequencing). The
sequence results were obtained in pyrogram formats.
Data Cleaning
SNP genotyping yielded an initial 374 by 19,628 matrix, where
rows represent individuals, columns represent coding SNPs, and
entries represent SNP genotypes. After removing monomorphic
SNPs and rows/columns containing a high fraction of no-calls for
genotype, we were left with a 360 by 14,111 dimensional matrix X
in which 14 subjects (10 controls and four cases) were dropped.
This curated matrix had a genotyping efficiency (fraction of
nonmissing values) of 97.3%, and was compared to the
corresponding Boolean response vector Y, which had 177 controls
and 183 cases coded as 0 and 1, respectively.
SNP-Level Analysis
We began by conducting a univariate analysis to find individual
SNPs correlated with the case/control label. Target alleles for SNPs
from different studies were obtained from dbSNP build 127
[Wheeler et al., 2007] and lexicographically ordered to facilitate
comparison of allele frequencies. That is, in each case the X allele
was alphabetically first while the Yallele was alphabetically second,
with the primer sequence used to resolve inconsistencies among
C/G and A/T polymorphisms. We next tested each SNP for
deviation from Hardy-Weinberg equilibrium (HWE) [Salanti
et al., 2005] using Fisher’s exact test as implemented in the
genetics package [Warnes et al., 2007] in R, and checked the
validity of the missing-completely-at-random (MCAR) assump-
tion by calculating the Fisher test P value for the 2   2 table of
case/control responses vs. missing/nonmissing data. We then
computed several measures of association between each SNP and
the case/control response vector: the (natural) log odds ratio
[Agresti, 2002] and associated 95% confidence interval (CI),
Fisher’s exact tests for genotypic (FG) and allelic association (FA),
and logistic regression for dominant (D), additive (A), and
recessive (R) dosage models. SNPs that had log odds ratio CIs
wider than three were omitted as these corresponded to
contingency tables with low counts in one or more of the cells.
Following Lesnick et al. [2007], the best (minimum) P value over
these five association models was retained and SNPs were ranked
by this P value. We termed this minimum P value the ‘‘main
effect’’ of the SNP on the trait and the corresponding model the
‘‘best model’’ of the SNP (Table 1). The full version of Tables 1–4
are available as Supplementary Material.
Pathway-Level Analysis
Many whole genome association studies conclude by noting
that strongly associated SNPs fall within a given pathway. Rather
than invoking this information a posteriori, it is useful to bring it
in at the beginning of the analysis. Thus motivated, we developed
a statistical test for ranking pathways by their degree of
association, which controls for the confound of pathway size.
Regressing Labels on Dosages
We began by mapping SNPs to genes (using ASN flat files from
dbSNP [Wheeler et al., 2007] build 127) and genes to KEGG
[Kanehisa et al., 2008] pathways. For each pathway k,w e
constructed a predictor matrix Xk of SNP dosages and regressed
case/control coding Y on SNP dosages (Fig. 1A). We retained only
SNPs with minimum P-values less than 0.05 and coded SNPs
according to their best association model. For example, SNPs that
had their best P-value under the dominant model (D) were coded
as (XX,XY,YY) - (0,1,1), and similarly for the additive (A) and
recessive (R) models; SNPs that had their best P-value under the
Fisher allelic or genotypic models were coded as (0,1,2). We used
boosted decision trees [Ridgeway, 2007] to perform the regression
to allow for scattered missing values in the dosage matrices. Unlike
logistic regression, decision trees can naturally handle the
occurrence of nonmonotonicity of case proportions as a function
of allelic dosage, which is useful for regressing on SNPs that had
their best P values under the nonadditive FA or FG models. We
calculated the quality of the overall regression of Yon the pathway
matrix Xk by 10-fold bootstrap cross-validation. Specifically, we
randomly assigned 10% of the rows to a test set and 90% into a
training set and determined the median area under the receiver
operating characteristic (ROC) [Sing et al., 2005] curve (AUC) over
10 such splits. This median AUC ak was a nominal measure of the
association between variation in pathway k and the binary trait Y,
and ranged from 0.5 (no association) to 1.0 (perfect association).
Equivalent Odds Ratios Allow Comparison of SNP- and
Pathway-Level Associations
It is useful to relate the AUC to the odds ratio, which is the
standard figure of merit in a GWA study. To do this, let t be the true
positive rate, f be the false positive rate, R b et h eo d d sr a t i o ,a n dA be
the AUC. From the definitions [Agresti 2002; Sing et al., 2005] of
these quantities, for a given tA[0,1] and fA[0,1] we obtain:
R ¼
tð1   fÞ
fð1   tÞ
: ð1Þ
If instead we regard R as fixed, we can consider the set of all t vs. f
values that satisfy this equation to trace out an ROC curve [Pepe
230 HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009et al., 2004]. Though in practice a real ROC curve will have different
odds ratios along the curve, the AUC of this ‘‘constant odds ratio’’
ROC curve is useful for comparing the odds ratio (which measures
the association of a binary predictor, such as allele presence) with
the AUC (which measures the association of a continuous predictor,
such as the predicted proportion of cases). To calculate the AUC of
the ‘‘constant odds ratio’’ ROC curve we regard the true positive rate
t as a function of the false positive rate f and the odds ratio R.W e
c a nt h e nc a l c u l a t et h eA U CA as a function of the odds ratio R by
integration:
AðRÞ¼
Z 1
0
tðf;RÞdf ¼
Z 1
0
Rf
ðR   1Þf þ 1
df ¼
R
ðR   1Þ
2 ðR   InR   1Þ:
ð2Þ
It can be shown that limR-1 A(R)50.5 and limR-N A(R)51, and
that A(R) is monotonically increasing for RA[1,N]. This monotonic
relationship indicates that we can quote an ‘‘equivalent’’ AUC for a
given odds ratio or vice versa. Tables 2 and 3 contain these equivalent
odds ratios for the top ranked pathways in both studies, along with
95% CIs. These values are computed by empirically calculating the
inverse mapping from AUCs to odds ratios, R(A), and then evaluating
this mapping at the median AUC and the 0.025 and 0.975 percentile
AUCs. The utility of the equivalent odds ratios is that we can directly
compare nominal pathway associations to SNP associations in terms
of their overall odds ratios rather than quoting the odds ratio at a
particular position on the ROC curve.
Balancing Model Complexity vs. Model Fit
It is important to note that a pathway with more SNPs will tend
to have a higher nominal AUC than a pathway with less SNPs.
This is a manifestation of the well-known relationship between
model fit and model complexity [Gentle et al., 2004]; however, in
this particular circumstance we cannot simply maximize, e.g., the
Bayesian information criterion [Schwarz, 1978] because the
number of predictors (namely SNPs) is fixed in a given pathway.
Instead of doing this, we used two permutation controls. The first
control was to permute the rows of the response variable Y and
rerun the regression 500 times for each pathway matrix. This
control consistently yielded low AUCs for every pathway,
indicating that the pathway matrices were not large enough to
spuriously fit a random response variable. The second and more
rigorous control was a permutation-based approach to test
whether the collection of SNPs in pathway k carried more
predictive value than the same number of SNPs selected at
random. To do this, for each pathway k, we first determined the
number of statistically independent SNPs jk by using the Solid
Spine algorithm in Haploview [Barrett et al., 2005] to assign SNPs
to haplotype blocks in the pathway dosage matrix. The number of
independent SNPs jk in pathway k was the number of haplotype
blocks plus the number of SNPs not assigned to blocks. We then
sampled jk SNPs from the pool of all SNPs with minimum P
values below 0.05, which corresponded to permuting the SNP to
pathway mapping. We concatenated the corresponding SNP
columns to form a random dosage matrix with jk columns and
computed the 10-fold bootstrap cross-validated median AUC as
described above. We repeated this process 500 times to obtain the
empirical conditional distribution P(A|J), where A was the AUC
(the model fit) and J was the number of SNPs in the pathway (the
model complexity). In practice, there were often multiple
pathways with, e.g., 50 independent SNPs and no pathways with
53 independent SNPs; to compensate for this we ensured that
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HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009 231exactly 500 median AUCs were calculated for each possible J value
where J ranged from 1 to the maximum number of independent
SNPs in all observed pathways.
Smoothing Empirical Quantiles
The intent of doing this control was to compare the nominal
AUC ak to the distribution of random AUCs for matrices of the
same size, to determine a corrected P-value for pathway
significance. Intuitively, a pathway containing, e.g., five indepen-
dent SNPs that has a better nominal AUC than 495 out of 500
random matrices of five independent SNPs can be said to have an
corrected P value of approximately 5/50050.01, which is the
empirical quantile [Koenker, 2007]. However, the straightforward
approach of using empirical quantiles to compute corrected P
values presents a minor dilemma. We expect that the threshold for
a significant model fit should increase monotonically with the
model complexity. But if we naively calculate the conditional
empirical quantiles Qa[A|J] for each value of J ¼2 f1;...;jmaxg
and a ¼2 ½0;1 , because of sampling variance we will with high
Figure 1. Identifying pathway determinants of disease. A: For each pathway, we extracted the SNPs that mapped to genes in that pathway
and formed a dosage matrix in which columns were coded according to the best model of the corresponding SNP (see text). We then fit a
regression model (see text) to predict the case/control label Y from the matrix of SNP dosages Xk of pathway k. B: The plots contain density
estimates of the predicted probability of PD given variation in the axon guidance (KEGG 04360) and aminoacyl-tRNA biosynthesis (KEGG 00970)
pathways. Points along the abscissa represent patients, with cases in red and controls in blue. Intuitively, pathways in which variation is
strongly correlated with case/control status should show visible separation of the blue and red curves. By measuring this separation with the
AUC [Sing et al., 2005], a nonparametric measure of curve separation, we obtained a nominal measure of the fit of the regression model. C: An
important confound is that pathways with many SNPs will have spuriously high AUCs, a manifestation of the traditional tradeoff between model
fit and model complexity [Gentle et al., 2004]. To control for this, for each pathway we generated 500 random dosage matrices with the same
number of statistically independent SNPs (see text). We then calculated the AUC of the regression model fit on these 500 random matrices. By
estimating the empirical percentile of the nominal AUC relative to this permutation distribution, we computed a corrected P value for the
significance of the pathway/trait association. For example, in the figure we show density estimates of the permutation distribution of AUCs in
magenta relative to the nominal AUC in green for the axon guidance and focal adhesion pathways. In the left panel, the nominal AUC (green
point) for the axon guidance pathway is in the right tail of the magenta permutation distribution. Thus the axon guidance pathway shows a
stronger association with PD than a random pathway of the same size. By contrast, the nominal AUC of the focal adhesion is in the middle range
of its permutation distribution, indicating that the focal adhesion association is not statistically significant. D: The empirical percentile of the
nominal AUC relative to the permutation distribution gives us a P-value that measures pathway association, corrected for the number of SNPs in
the pathway. This allows us to rank pathways by their degree of association.
232 HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009Table 2. Pathways With the Highest Associations With PD in Our Study
KEGG Annotation Nominal AUC (95% CI) Equivalent log OR 95% CI) P value
04120 Ubiquitin-mediated proteolysis 0.66 (0.62–0.70) 0.99 (0.74–1.24) 0.01
00340 Histidine metabolism 0.61 (0.57–0.63) 0.68 (0.43–0.82) 0.04
04360 Axon guidance 0.69 (0.65–0.74) 1.18 (0.92–1.54) 0.04
04660 T cell receptor signaling pathway 0.63 (0.58–0.67) 0.81 (0.49–1.02) 0.04
00030 Pentose phosphate pathway 0.62 (0.57–0.65) 0.72 (0.43–0.91) 0.09
04012 ErbB signaling pathway 0.63 (0.61–0.71) 0.82 (0.63–1.32) 0.1
04612 Antigen processing and presentation 0.62 (0.56–0.65) 0.71 (0.36–0.94) 0.1
00511 N-Glycan degradation 0.63 (0.56–0.66) 0.81 (0.34–1.01) 0.11
00561 Glycerolipid metabolism 0.65 (0.61–0.69) 0.90 (0.69–1.18) 0.11
04610 Complement and coagulation cascades 0.69 (0.65–0.74) 1.17 (0.92–1.52) 0.11
Pathways are ranked by their P value corrected for the number of SNPs in the pathway; full tables are available as Supplementary Material online. The table contains the
nominal AUC and the equivalent nominal log odds ratios along with 95% CIs computed as described in the text in Table 2. This nominal AUC is used to compute the corrected
p-value from the AUC permutation distribution as in Figures 1C and 2. Note that the log odds ratios for pathway-level associations are generally higher than those for single
SNPs; this is both expected and desirable, as pathway-level associations are based on several SNPs.
KEGG, Kyoto Encyclopedia of Genes and Genomes (www.genome.jp/kegg).
Table 3. Pathways With the Highest Associations With PD in the Fung et al. [2006] Study, Ranked by P-Value Corrected for the
Number of SNPs in
the Pathway
KEGG Annotation Nominal AUC 95% CI) Equivalent log OR (95% CI) P value
05131 Pathogenic E. coli infection; EPEC 0.74 (0.69–0.76) 1.53 (1.19–1.71) 0.02
04530 Tight junction 0.81 (0.77–0.85) 2.15 (1.82–2.53) 0.03
05130 Pathogenic E. coli infection; EHEC 0.73 (0.71–0.76) 1.49 (1.3–1.7) 0.03
00561 Glycerolipid metabolism 0.74 (0.71–0.78) 1.58 (1.35–1.85) 0.07
00980 Metabolism of xenobiotics by cytochrome P450 0.69 (0.66–0.73) 1.2 (0.98–1.51) 0.07
04620 Toll-like receptor signaling pathway 0.74 (0.71–0.76) 1.56 (1.35–1.71) 0.07
04150 mTOR signaling pathway 0.72 (0.69–0.75) 1.43 (1.2–1.59) 0.08
00590 Arachidonic acid metabolism 0.7 (0.67–0.73) 1.27 (1.04–1.49) 0.1
00252 Alanine and aspartate metabolism 0.67 (0.64–0.7) 1.07 (0.85–1.27) 0.11
00532 Chondroitin sulfate biosynthesis 0.72 (0.69–0.76) 1.43 (1.21–1.74) 0.12
See Table 2 for details on column headers.
KEGG, Kyoto Encyclopedia of Genes and Genomes (www.genome.jp/kegg).
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Figure 2. Pathways with more SNPs require higher association levels to reach significance. In each panel, the green points represent
pathways and the curves depict the conditional quantiles of the permutation distribution of AUC values given the number of SNPs in a pathway
(see text). This plot allows us to determine which (if any) pathways exceed statistical significance in a given study. For example, pathways that
lie above the 0.99 quantile curve have a higher nominal AUC than 99% of random pathways with the same number of independent SNPs, and
hence have an empirical P value of 0.01. As noted in the text, there are four pathways that exceed the P50.05 level in our study (A), and two
that exceed this level in the Fung et al. [2006] study (B).
HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009 233probability encounter a situation in which the quantiles are no
longer monotonically increasing:
Q0:05½AjJ ¼ j1 4Q0:05 ½AjJ ¼ j2 ðwhere; j1oj2Þ: ð3Þ
This corresponds to the undesirable situation in which the
threshold for significance of the model fit at the a50.05 level is
decreasing despite an increase in the number of independent SNPs
in the pathway. To avoid this, we used quantile regression
[Koenker, 2007] to fit a nondecreasing set of quantile curves
(Fig. 2) to the A vs. J scatterplot. Superimposing the (ak, jk) values
upon these curves gives us an immediate, visual diagnosis of
which pathways have a model fit that is statistically significant
relative to their number of independent SNPs (Fig. 2). These
significance levels are enumerated in Tables 2 and 3 for both
studies. Note that an alternative to this correction based on
empirical quantiles of a permutation distribution would have been
to use linear regression to partial out the effect of the number of
independent SNPs on the nominal AUC, using the rank ordering
of the resulting residuals as an ordering of pathway association
strengths. However, correcting the nominal AUC-induced rank-
ordering in this fashion would require the assumption of a linear
relationship between the number of independent SNPs and the
nominal AUC, an assumption which Figure 2 indicates is clearly
violated.
Results
We performed the SNP-level analyses for our dataset as well as
the Fung et al. [2006] and Lesnick et al. [2007] datasets. Because
individual-level data for the Lesnick et al. [2007] study was not
available at the time of writing, we only conducted pathway-level
analyses for our study and Fung et al.’s [2006] study.
Replication of the Axon Guidance Pathway Association
As shown in Figure 2A and Table 2, one of our most interesting
findings was that the axon guidance pathway (KEGG 04360)
previously reported by Lesnick et al. [2007] as associated with PD
came up as the third most significant pathway in our study after
controlling for the number of SNPs, with ubiquitin pro-
teolysis (KEGG 04120), histidine biosynthesis (KEGG 00340),
and T-cell receptor signaling (KEGG 04660) at 1, 2, and 4,
respectively. Though the apparent significance of ubiquitin
proteolysis is intriguing given the known biology of PD
[Rubinsztein, 2006], there were only two SNPs in this significant
pathway (Table 4).
More puzzling, though, as shown in Figure 2B and Table 3, we
find that axon guidance does not rank highly in the Fung et al.
[2006] study after controlling for pathway size. Instead, the tight
junction (KEGG 04530) and the pathogenic E. coli enterohemor-
rhagic E. coli (EHEC) and enteropathogenic E. coli (EPEC)
pathways (KEGG 05130 and 05131, respectively) are the most
highly ranked, despite an identical analytic approach. This lack of
association between axon guidance and PD in the Fung et al.
[2006] dataset may appear to contradict the results of Lesnick
et al. [2007], but there is a key difference. In the Lesnick et al.
[2007] study, the nominal axon guidance pathway association was
computed from a set of SNPs thresholded for main effects with P
values better than 0.05, but the significance of the association was
tested by sampling from a pool of SNPs that was not thresholded
for main effects.
Using our notation, this results in a downshifted permutation
distribution of P(A|J) and hence an inflated empirical P value for
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234 HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009the significance of any given pathway. While entirely under-
standable given that their work was a ‘‘candidate pathway’’
analysis rather than a comparative analysis of pathway signifi-
cance, it nonetheless points to the necessity of systematically
controlling for the number of SNPs in a pathway (model
complexity) when evaluating the significance of a candidate
pathway association (model fit).
SNP Frequencies Globally Replicate
Spurred by the finding that the axon guidance association
appeared to partially but not completely replicate, we performed
a detailed comparison of the three datasets, as summarized in
Figure 3. We began by checking whether a disparity in assayed
SNPs could account for the discrepancy. In Figure 3A–C, we see
that SNP frequencies mostly match for the SNPs shared between
our study and the Maraganore et al. [2005] and Fung et al. [2006]
studies. This result is heartening because the underlying technol-
ogies are quite different: Fung et al. [2006] assayed 408,803 SNPs
on the Illumina Infinium I and HumanHap300 platforms; Lesnick
et al. [2007] assayed 248,535 SNPs on a Perlegen array; and we
assayed 19,628 SNPs on the MegAllele Genotyping Human 20K
cSNP platform. Nevertheless, Figure 3A–C indicates technical
replication of SNP frequencies between the studies.
Interestingly, we also observed that even SNPs that were out of
HWE in one or more studies tend to replicate in frequency
between studies. For example, the conditional correlation in allele
frequencies between our study and Fung et al. [2006] for SNPs out
of HWE is 0.919 (95% CI, 0.903–0.933), which is fairly high; in
comparison, the conditional correlation in allele frequencies that
Figure 3. SNP allele frequencies correlate between studies but odds ratios do not. In all panels, points represent SNPs. A–C: Scatterplots of
SNP allele frequencies between all three studies. D–F: Scatterplots of log odds ratios between studies. In each panel a locally linear LOWESS fit
is superimposed. As noted in the text, allele frequencies clearly correlate at a global level but odds ratios do not.
HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009 235do not deviate from HWE is 0.9927 (95% CI, 0.9923–0.9931).
Similar tendencies hold for individual genotype frequencies.
Thus, though deviation from HWE has been recommended as a
quality control step in WGA [Leal, 2005], simply dropping SNPs
that deviate from HWE may be premature. In particular,
reproducible deviations from Mendelian inheritance patterns
may indicate the presence of a copy number variant [Estivill
and Armengol, 2007].
SNP and Pathway Associations Do Not Globally Replicate
In Figure 3D–F, we see that SNP associations do not globally
correlate between studies. These results might be partially
rationalized by noting that only a small set of SNPs might be
expected to replicate, with all other associations at the level of
noise; however, if this were the case we would expect to see a
mixture distribution for the log odds ratio scatterplot, which
consisted of a large bivariate normal of noisy, nonreplicated SNPs
in the center and a small, tapering line of SNPs in the upper right
and lower left corner of the plot, with reproducibly positive/
negative log odds ratios. This tapering line is not observed. Figure
4 is a global comparison of pathway-level associations against the
same disease between studies. Some have hypothesized that
pathways replicate, but SNPs do not, by analogy to similar results
in expression analysis [Subramanian et al., 2005]; however, in this
case no overall correlation is apparent. Ubiquitin proteolysis, for
example, is the most significant in our study and among the least
significant in Fung et al. [2006]. It is, however, interesting to note
that glycerolipid metabolism (KEGG 00561) is near the boundary
of significance in both studies.
Discussion
We have developed a method for ranking pathways by their
degree of association with a trait of interest, which controls for the
number of SNPs in the pathway. We applied this method to our
own WGAS as well as two recent studies by Fung et al. [2006] and
Maraganore et al. [2005]. We showed that pathway associations
can be directly compared to SNP associations by calculating an
equivalent odds ratio, and that in general the log odds ratios for
pathway-level associations (Table 2) are higher than those for
single SNPs; this is both expected and desirable, as pathway-level
associations are based on several SNPs. Top-ranking pathways
included ubiquitin proteolysis, histidine biosynthesis, T-cell
receptor signaling, and axon guidance. In a parallel study, we
performed a high-resolution linkage analysis, using a 500K SNP
chip, on familial Parkinsonian-pyramidal syndrome and could
identify FBXO7 (MIM] 605648) as the likely disease-causing gene
[Shojaee et al., 2008]. Interestingly, FBXO7 is part of the E3-ligase
complex which is involved in ubiquitin-proteasome pathway,
providing yet another validation of the importance of this
pathway in the etiology of PD. We also found that the SNPs that
are highly ranked in a univariate context (Table 1) are not the
most significant SNPs in a multivariate, pathway context (Table 4).
Both of these findings indicate that the simultaneous use of
multiple SNPs is likely to increase diagnostic reproducibility over
the use of one SNP at a time, a result similar to that found with
expression microarrays [Subramanian et al., 2005]. As a particular
example of a potentially reproduced result, we found partial
replication of the previously reported axon guidance/PD associa-
tion [Lesnick et al., 2007] in our study (Fig. 2), but observed that
the overall reproducibility of SNP and pathway associations is
poor (Figs. 3D–F and 4). Though it is tempting to state that
differences in assayed SNPs are responsible for the discrepancies
between pathway associations in our study and the Fung et al.
[2006] study, Figure 3 partially argues against this conclusion as
shared SNPs appear quite similar in terms of allele (and genotype)
frequencies. It is more likely that the difference between the
studies is in the genotype-to-phenotype map rather than the
genotype matrices themselves; using the notation in Figure 1, this
corresponds to a difference in P(Y|X) rather than in P(X).
The discrepancy between associated pathways can likely be
remediated by modifying current protocols for genotyping,
phenotyping, and data analysis. In terms of phenotyping, we
recommend that future studies assay many more phenotypes,
including molecular and biochemical traits (e.g., blood levodopa
0.0 0.2 0.4 0.6 0.8
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
C
o
r
r
e
c
t
e
d
 
p
-
v
a
l
u
e
 
(
F
u
n
g
 
e
t
 
a
l
.
)
1
2
3
4
5
6 7
89
10
11
13
12
Index Pathway Annotation KEGG
1 Ubiquitin mediated proteolysis 04120
2 Histidine metabolism 00340
3 T-cell receptor signaling 04660
4 Axon guidance 04360
5 Pentose phosphate pathway 00030
6 Glycerolipid metabolism 00561
7 Toll-like receptor signaling pathway 04620
8 Pathogenic E. coli (EHEC) 05130
9 Pathogenic E. coli (EPEC) 05131
10 mTOR signaling pathway 04150
11 Arachidonic acid metabolism 00590
12 Cytochrome P450 metabolism 00980
13 Tight junction 04530
Corrected p-value (this study)
Figure 4. Pathway associations do not globally correlate between studies. In the plot, each point represents a pathway, and the vertical and
horizontal dashed lines represent the P50.05 thresholds in our study and the study by Fung et al. [2006], respectively. Pathways near the
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236 HUMAN MUTATION, Vol. 30, No. 2, 228–238, 2009levels), in addition to high-level Boolean phenotypes such as case/
control status. This is because basic phenotypes are easier to
explain in terms of molecular variation; for example, it is easier to
predict expression levels [Spielman et al., 2007] from SNP data
than it is to predict height [Visscher et al., 2007]. With respect to
genotyping, we believe that future studies should involve as many
different features as possible in addition to SNP genotyping,
including expression arrays and copy number variants [Estivill
and Armengol, 2007]. In particular, we expect that studies of
standing variation in copy numbers will produce more consistent
matches to existing molecular results because manipulation of
gene dosage (via knockout, knockdown, and overexpression) is
the stock-in-trade of molecular biology.
Finally, with respect to data analysis, the discrepancies observed
here between different studies are reminiscent of the early days of
microarrays. There, too, conflicting results [Miklos and Maleszka,
2004] were eventually resolved after many large data sets were
combined with the adoption of a systematic, Bayesian integration
strategy [Jansen et al., 2003; Lee et al., 2004; Srinivasan et al.,
2007]. A similar integration methodology in the context of WGA
is a fruitful topic for further research.
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